Navigation Links
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Date:5/1/2008

-- Presentations highlight Palomid 529 as an inhibitor of macular

degeneration, diabetic retinopathy and retinal scaring from retinal

detachment in animal disease models ---

JAMAICA PLAIN, Mass., May 1 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented two presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) describing the activity of Palomid 529 in a series of models of retinal disease notably macular degeneration, diabetic retinopathy and retinal fibrosis.

P529 is a non-steroidal, synthetic, small molecule drug created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic and anti-proliferative agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the two presentations, "Palomid 529, a Non-Steroidal Small Molecule Anti-Angiogenic Agent Inhibits Retinal and Subretinal Neovascularization by Inhibiting the PI3K/Akt/mTOR Pathway", was given as an oral presentation by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Muller Cell Proliferation and Glial Scar Formation Is Reduced Following Experimental Retinal Detachment Using Palomid 529, an Inhibitor of the Akt/mTOR Pathway", was given by the Drs. Geoffrey P. Lewis and Steven. K. Fisher, presented by Dr. Ethan A. Chapin, of the Neuroscience Research Institute, Neuroscience Research Institute, MCD Biology, University of California-Santa Barbara, Santa Barbara, CA.

"Ocular diseases of both retinal and sub-retinal origin, namely diabetic retinopathy and age-related macular degeneration, are a significant problem in our aging population. In order to create a drug to optimally treat such diseases one needs to prevent or inhibit disease pr
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
2. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
5. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
7. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
8. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
10. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... With the swift industrial development of ... as smart phones, tablets and PDAs, a complete change ... devices are viewed these days. From only being used ... a mode for creating and delivering content while on ... , The complete makeover of this (mobile) ...
(Date:9/18/2014)... County, NY (PRWEB) September 18, 2014 ... Westchester residents, community advocates, and volunteers supported United ... annual “Best Chefs and Fine Wines” event Monday, Sept. ... United Way’s health initiatives in Westchester and Putnam, such ... obesity, and steering teens away from risky behaviors like ...
(Date:9/18/2014)... common Asian spice and cancer-hampering molecules show promise ... of the lung,s lining often linked to asbestos. ... Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of ... cancer-inhibiting peptides increase levels of a protein inhibitor ... Their findings appeared in the Aug. 14 online ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 October ... also Domestic Violence Awareness Month. And the Centers for ... tells a scary story. , According to the CDC ... fourth of men in the U.S. experience some form ... intimate relationship. The same survey shows that about half ...
(Date:9/18/2014)... 2014 With the arrival of subsequent-entry biologics ... Society released new resources to educate stakeholders on their potential ... guide SEB use, and patients must be well informed when ... Click here for an infographic and an expert video ... here for The Arthritis Society’s position paper on SEBs. ...
Breaking Medicine News(10 mins):Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3Health News:What you should know about domestic violence 2Health News:What you should know about domestic violence 3Health News:What you should know about domestic violence 4Health News:What you should know about domestic violence 5Health News:Subsequent-entry biologics set to alter the arthritis treatment landscape 2
... Volumizing ... ... of the eyes change in generally predictable ways: the skin thins and becomes less elastic, ... eyes appear more prominent. While surgery has long been the accepted standard and offers ...
... , COLD SPRING HARBOR, N.Y., Aug. 17 ... Doctors Laboratory (TDL), the largest independent provider of clinical laboratory ... the world,s first hand-held, non-contact vein illumination device, to the ... locate veins for blood draw (venipuncture) by projecting a pattern ...
... , ALBANY, N.Y., Aug. 17 The ... August 17, 2009, is an Air Quality Action Day, a ... such as children, seniors and people with asthma and other ... pollution. The alert is issued for the New York downstate ...
... , , MCLEAN, Va., Aug. 17 ... His Cookie Helped 500,000 People Lose Weight Fast (2009, Hyde ... at CookieDiet.com, Amazon.com, Borders.com, and BN.com; at Barnes & Noble stores ... Biggest Bookstore, and Coles. , , "Dr. Siegal,s ...
... Finding will help predict patient response to therapy, researchers say ... that predicts a patient,s response to hepatitis C treatments has ... a single letter change -- a C instead of a ... gene, according to the Duke University Medical Center team. They ...
... , PRINCETON, N.J., Aug. 17 Derma ... a provider of advanced wound care products, reports results today for the second quarter ... for second quarter and six months ended June 30, 2009: , , ... to $664,766 in second quarter 2009, versus $295,315 in 2008. For the six months ...
Cached Medicine News:Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3Health News:AccuVein Sells Multiple AV300s to First European Customer 2Health News:Air Quality Action Day Declared for Monday, August 17, 2009 2Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 2Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 3Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 4Health News:Genetic Discovery May Improve Hepatitis C Treatment 2Health News:Derma Sciences Reports Second Quarter 2009 Results 2Health News:Derma Sciences Reports Second Quarter 2009 Results 3Health News:Derma Sciences Reports Second Quarter 2009 Results 4Health News:Derma Sciences Reports Second Quarter 2009 Results 5Health News:Derma Sciences Reports Second Quarter 2009 Results 6Health News:Derma Sciences Reports Second Quarter 2009 Results 7Health News:Derma Sciences Reports Second Quarter 2009 Results 8
(Date:9/18/2014)... , Sept. 18, 2014  Casen Buswell has a ... muscles to harden.  His case is one of only 14 ... world.  The only hospital in the United States ... world, offering treatment with the dual wave-length laser, is Methodist ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds ... the United States , 54 percent of ... inhibitor Tafinlar for BRAF -mutation-positive unresectable or ... prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current non-prescribers ... percent and 43 percent, respectively) expects to prescribe ...
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, 2014 /PRNewswire/ ... of innovative approaches to diagnosing and treating Autism Spectrum ... an Exclusive License Agreement with The Research Foundation for ... this Agreement, Iliad will provide a new biomarker to ... associated with susceptibility to ASD. This biomarker is expected ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3
... , COLLEGE STATION, ... , MD, FACS, of The Texas Institute for Thyroid and Parathyroid ... College Station Medical Center in College Station, Texas . ... in North America to be recognized by Intuitive Surgical ...
... , Jan. 14 In the keynote address at ... Lechleiter , Ph.D., chairman and CEO of Eli Lilly and Company, ... edge in innovation and improving our focus on medical innovation,s richest ... in the coming decade.  His speech focused on bioscience innovation, a ...
Cached Medicine Technology:Milestone Achieved in Revolutionary Robotic Thyroid Surgery 2Lilly CEO Stresses Human Element in Driving Medical Innovation 2Lilly CEO Stresses Human Element in Driving Medical Innovation 3
Resorbable fixation system 1.5/2.0....
... Sonomed-315 is intended for visualization of the ... midline shifts in the brain, evaluation of ... to use, the Sonomed-315 offers quick and ... allows to identify the anatomic structures of ...
... cost, low volume alternative. Whole blood is drawn ... from whole blood by centrifugation in a standard ... Cebus single use cartridge. The cartridge is then ... the concentrating process. Finally, the cartridge is spun ...
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: